A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 9, 2012, Pages 3179-3184

  Bible, Keith C ^a   Suman, Vera J ^a   Menefee, Michael E ^b   Smallridge, Robert C ^b   Molina, Julian R ^a   Maples, William J ^b   Karlin, Nina J ^c   Traynor, Anne M ^d   Kumar, Priya ^e   Goh, Boon Cher ^f   Lim, Wan Teck ^g   Bossou, Ayoko R ^a   Isham, Crescent R ^a   Webster, Kevin P ^a   Kukla, Andrea K ^a   Bieber, Carolyn ^b   Burton, Jill K ^a   Harris, Pamela ^h   Erlichman, Charles ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^g DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAZOPANIB;

ADULT; ADVANCED CANCER; AGED; ANAPLASTIC THYROID CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTHRALGIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART ATRIUM FIBRILLATION; HOT FLUSH; HUMAN; HYPERTENSION; HYPOPIGMENTATION; IN VIVO STUDY; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAGNESIUM BLOOD LEVEL; MALE; MONOTHERAPY; MOUSE; MULTICENTER STUDY; MYALGIA; NAUSEA; NECK PAIN; NEUTROPHIL COUNT; NONHUMAN; PATIENT ASSESSMENT; PHASE 2 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SODIUM BLOOD LEVEL; SORE THROAT; SURVIVAL TIME; SWEATING; TASTE DISORDER; THROMBOCYTE COUNT; THROMBOSIS; THYROID CARCINOMA; TRACHEITIS; VASCULAR DISEASE; VOMITING;

AGED; ANIMALS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; SURVIVAL ANALYSIS; THYROID NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866168936     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1520     Document Type: Article

References (19)

1. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA, Goellner JR 2001 Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130:1028-1034 (Pubitemid 34014569)
2. Smallridge RC, Copland JA 2010 Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol) 22:486-497
3. Ain KB, Egorin MJ, DeSimone PA 2000 Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-sixhour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10:587-594 (Pubitemid 30670619)
4. Kawada K, Kitagawa K, Kamei S, Inada M, Mitsuma A, Sawaki M, Kikumori T, Fujimoto Y, Arima H, Imai T, Ando Y 2010 The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol 40:596-599
5. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC 2002 A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408-3416 (Pubitemid 34651387)
6. Mooney CJ, Nagaiah G, Fu P, Wasman JK, Cooney MM, Savvides PS, Bokar JA, Dowlati A, Wang D, Agarwala SS, Flick SM, Hartman PH, Ortiz JD, Lavertu PN, Remick SC 2009 A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 19:233-240
7. Shimaoka K, Schoenfeld DA, De Wys WD, Creech RH, DeConti R 1985 A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155-2160 (Pubitemid 16236586)
8. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719
9. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely Jr PE, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684
10. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris 3rd JC, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C; Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer Center; Mayo Phase 2 Consortium 2010 Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 11:962-972
11. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713
12. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG 2010 Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 16:5260-5268
13. Wells Jr SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, SchlumbergerMJ2012 Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind Phase III trial. J Clin Oncol 30:134-141
14. Isham CR, Negron V, Lingle WL, Fisher KE, Kumar R, Bible KC Pazopanib potentiates paclitaxel-induced mitotic catastrophe in association with inhibition of aurora kinases. Proceedings of the Proc 102nd Annual Meeting of the American Association for Cancer Research, Orlando, Florida, 2011 (Abstract 3597)
15. Sargent DJ, Chan V, Goldberg RM 2001 A three outcome design for phase II clinical trials. Controlled Clinical Trials 22:117-125 (Pubitemid 32289448)
16. Nagaiah G, Fu P, Wasman JK, Cooney MM, Mooney C, Afshin D, Lavertu P, Bokar J, Savvides P, Remick SC 2009 Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC). J Clin Oncol 27:15 (Suppl abstr 6058)
17. Ha HT, Lee JS, Urba S, Koenig RJ, Sisson J, Giordano T, Worden FP 2010 A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 20:975-980
18. Koussis H, Maruzzo M, Scola A, Ide EC, Fassina A, Marioni G, Lora O, Corti L, Karachontziti P, Jirillo A 2010 A case of anaplastic thyroid cancer with long-term survival. Anticancer Res 30:1273-1278
19. Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC, Bible KC 2011 Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single institution experience using aggressive multimodal therapy. Thyroid 21:25-30